干扰素治疗丙型肝炎感染：历史视角。
Treatment of hepatitis C infections with interferon: a historical perspective.
作者信息
Friedman Robert M, Contente Sara
机构信息
Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
出版信息
Hepat Res Treat. 2010;2010:323926. doi: 10.1155/2010/323926. Epub 2010 Sep 6.
Abstract
Interferons were first described in 1957, but it was not until 34 years after their discovery that sufficient quantities of it were available for treatment of hepatitis C virus (HCV) infections, Clinicians now have an excellent understanding of the basis for the effectiveness of interferon alpha (IFN-α) in the therapy of this disease. Treatment with IFN-α is more efficient when it complemented by the antiviral ribavirin and the IFN-α is conjugated with polyethylene glycol to form peginterferon. In the near future treatment of HCV with IFN-α may involve new anti-HCV agents that are currently under development.
摘要
干扰素于1957年首次被描述，但直到其发现34年后，才有足够数量的干扰素可用于治疗丙型肝炎病毒（HCV）感染。临床医生现在对α干扰素（IFN-α）治疗这种疾病的有效性基础有了很好的理解。当与抗病毒药物利巴韦林联合使用且IFN-α与聚乙二醇结合形成聚乙二醇干扰素时，用IFN-α治疗更有效。在不久的将来，用IFN-α治疗HCV可能会涉及目前正在研发的新型抗HCV药物。
相似文献
1
Treatment of hepatitis C infections with interferon: a historical perspective.干扰素治疗丙型肝炎感染：历史视角。
Hepat Res Treat. 2010;2010:323926. doi: 10.1155/2010/323926. Epub 2010 Sep 6.
2
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.聚乙二醇干扰素治疗慢性丙型肝炎：聚乙二醇干扰素-α-2a 和聚乙二醇干扰素-α-2b 的药理学和临床差异。
Drugs. 2010;70(2):147-65. doi: 10.2165/11531990-000000000-00000.
3
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.聚乙二醇干扰素α-2a联合利巴韦林与干扰素α-2b联合利巴韦林作为初治慢性丙型肝炎初始治疗的成本效益
Pharmacoeconomics. 2004;22(4):257-65. doi: 10.2165/00019053-200422040-00004.
4
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.聚乙二醇干扰素α-2a联合利巴韦林与聚乙二醇干扰素α-2a单药治疗初治慢性丙型肝炎患者早期病毒学应答者的疗效比较，以及聚乙二醇干扰素α-2a联合利巴韦林与聚乙二醇干扰素α-2a、利巴韦林及金刚烷胺三联疗法治疗早期病毒学无应答者的疗效比较：SMIEC II试验
Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.
5
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.聚乙二醇干扰素 α 和利巴韦林治疗适合缩短疗程、再治疗或合并 HCV/HIV 感染的慢性丙型肝炎患者：系统评价和经济评估。
Health Technol Assess. 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170.
6
Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.聚乙二醇干扰素单独使用或与利巴韦林联合使用可增强慢性丙型肝炎患者的HCV特异性CD4辅助性T细胞1型反应。
Gastroenterology. 2002 Oct;123(4):1070-83. doi: 10.1053/gast.2002.36045.
7
Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.携带 IL28B 基因变异的人源化肝细胞的人和嵌合小鼠给予聚乙二醇干扰素-α后的丙型肝炎病毒动力学。
Gut. 2013 Sep;62(9):1340-6. doi: 10.1136/gutjnl-2012-302553. Epub 2012 Nov 7.
8
Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.聚乙二醇干扰素α-2a联合利巴韦林或聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎患者后的早期病毒学应答
J Viral Hepat. 2007 Oct;14(10):721-9. doi: 10.1111/j.1365-2893.2007.00862.x.
9
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.聚乙二醇干扰素α-2a（40kDa）联合利巴韦林治疗HIV与丙型肝炎病毒合并感染患者的成本效益分析
J Clin Virol. 2006 Aug;36(4):283-91. doi: 10.1016/j.jcv.2006.04.008. Epub 2006 Jun 9.
10
[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].[丙型肝炎病毒感染——12年后。慢性丙型肝炎管理的进展]
Orv Hetil. 2002 Dec 1;143(48):2667-74.
引用本文的文献
1
A Novel Antiviral Therapeutic Platform: Anchoring IFN-β to the Surface of Infectious Virions Equips Interferon-Evasive Virions with Potent Antiviral Activity.一种新型抗病毒治疗平台：将干扰素-β锚定在感染性病毒粒子表面赋予逃避干扰素的病毒粒子强大的抗病毒活性。
Viruses. 2025 May 13;17(5):697. doi: 10.3390/v17050697.
2
Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients.慢性乙型或丙型肝炎感染患者肝癌的三级预防
Cancers (Basel). 2021 Apr 6;13(7):1729. doi: 10.3390/cancers13071729.
3
Host-Directed Antiviral Therapy.宿主导向性抗病毒治疗
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00168-19. Print 2020 Jun 17.
4
Impact of Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.基因变异对丙型肝炎病毒基因型 3 患者持续病毒学应答和病毒血症的影响。
J Interferon Cytokine Res. 2019 Oct;39(10):642-649. doi: 10.1089/jir.2019.0013. Epub 2019 Jul 1.
5
Stem Cell-Derived Exosomes: A Potential Alternative Therapeutic Agent in Orthopaedics.干细胞衍生的外泌体：骨科领域一种潜在的替代治疗剂。
Stem Cells Int. 2016;2016:5802529. doi: 10.1155/2016/5802529. Epub 2016 Jan 19.
本文引用的文献
1
Telaprevir for previously treated chronic HCV infection.替拉瑞韦治疗既往治疗的慢性 HCV 感染。
N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014.
2
Risk for renal cell carcinoma in chronic hepatitis C infection.慢性丙型肝炎感染与肾细胞癌风险。
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1066-73. doi: 10.1158/1055-9965.EPI-09-1275. Epub 2010 Mar 23.
3
Hepatitis C virus: molecular biology & current therapeutic options.丙型肝炎病毒：分子生物学与当前治疗选择。
Indian J Med Res. 2010 Jan;131:17-34.
4
RIGorous detection: exposing virus through RNA sensing.精准检测：通过 RNA 感知揭示病毒。
Science. 2010 Jan 15;327(5963):284-6. doi: 10.1126/science.1185068.
5
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.IL28B 基因变异与慢性丙型肝炎及治疗失败相关：一项全基因组关联研究。
Gastroenterology. 2010 Apr;138(4):1338-45, 1345.e1-7. doi: 10.1053/j.gastro.2009.12.056. Epub 2010 Jan 11.
6
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.治疗相关肝毒性对 HCV 阳性非霍奇金淋巴瘤患者结局的影响。
Am J Hematol. 2010 Jan;85(1):46-50. doi: 10.1002/ajh.21564.
7
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.聚乙二醇干扰素 α2a 联合利巴韦林与聚乙二醇干扰素 α2b 联合利巴韦林治疗慢性丙型肝炎的随机研究。
Gastroenterology. 2010 Jan;138(1):108-15. doi: 10.1053/j.gastro.2009.08.071. Epub 2009 Sep 18.
8
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.聚乙二醇干扰素α-2b或α-2a联合利巴韦林用于治疗丙型肝炎感染。
N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22.
9
A step forward in therapy for hepatitis C.丙型肝炎治疗的一项进展。
N Engl J Med. 2009 Apr 30;360(18):1899-901. doi: 10.1056/NEJMe0901869.
10
Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.丙型肝炎病毒核心基因的突变与晚期肝病和肝细胞癌相关。
Clin Cancer Res. 2009 May 1;15(9):3205-13. doi: 10.1158/1078-0432.CCR-08-2418. Epub 2009 Apr 21.
Zotero 插件